India's generic drug industry began to flourish in the 1970s when India disallowed the patenting of medicines, enabling domestic companies, which did not have to invest in research, to make copies of branded drugs at a far lower cost. In 2005, India allowed patenting, but set the bar higher for patents than other countries. Novartis went to court in 2006 after India turned down a patent for Gleevek - a medicine used to treat leukemia. Indian authorities argue it is not a new medicine, but a ...
No comments:
Post a Comment